Moderna’s Stephen Hoge sells shares under trading plan (NASDAQ: MRNA)

What happened

Stephen Hoge, president of Moderna, Inc. (NASDAQ: MRNA), sold 78,369 shares from 2026-10-14 to 2026-10-15 for about $17.01 million. The shares traded at $213.47 to $220.72 per share. The filing says the sales were made under a Rule 10b5-1 trading plan adopted on June 15, 2026.

It also says the shares sold came from stock options exercised the same day. Hoge held 1,636,565 shares after the sale. The report lists 76,453 option shares exercised on 10/14/2026 and 76,452 on 10/15/2026 at $12.21.

Key numbers

Metric	Latest	Change	Source
Shares sold	78,369 shares		SEC Form 4
Sale price range	$213.47 to $220.72 per share		SEC Form 4
Total sale value	about $17.01 million		SEC Form 4
Shares held after sale	1,636,565 shares		SEC Form 4
Option shares exercised on 2026-10-14	76,453 shares		SEC Form 4

Read more: Moderna (MRNA) stock analysis and investment case

Why it matters

OptimistFi's case is that Moderna can create value if mRNA becomes a repeatable multi-product engine, and this filing is mixed for that view. The sale lowers Hoge's direct common-stock exposure, but the prearranged plan keeps the report from reading as a fresh comment on Moderna's prospects. The strongest caveat is in the filing itself, because the trades were tied to same-day option exercises rather than a stand-alone open-market disposal.

The filing is useful because it gives both the trade terms and the ownership level around the trade. Hoge sold 78,369 shares at a stated price range, then kept 1,636,565 shares, so the report shows a continuing stake even after the disposal. It also says the trades were made under a Rule 10b5-1 trading plan adopted on June 15, 2026, and that the shares sold came from stock options exercised the same day.

The 78,369 shares sold were about 4.6% of the 1,714,934 shares Hoge held before the trade.

That makes this a change in ownership, not an operating update, and the Rule 10b5-1 plan is the key context for reading it.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

The options tied to the trade expire on 02/23/2027. Another Form 4 before that date would show whether Hoge keeps selling under the same plan, while no follow-on filing would leave this as a single planned disposal. If later transactions appear, they will clarify whether the same 10b5-1 plan continues through 02/23/2027.

More from OptimistFi

• MRNA stock: the Moderna thesis, its status and the next test to watch
• Stock research on every company OptimistFi covers

From OptimistFi Perps